A new monthly weight loss drug developed by Amgen has shown promising results in a phase 2 trial, with participants losing roughly 20% of their body weight. If further testing confirms its safety and effectiveness, this could be a game-changer for people struggling with obesity—offering a simpler, less frequent dosing option compared to current weekly injections.

Editor’s Note: Obesity is a massive global health challenge, and existing treatments often require frequent injections or lifestyle changes that are hard to sustain. A monthly drug could make weight loss more accessible and manageable for millions. While it’s still early days (phase 2 trials are mid-stage), this could signal a major shift in how we approach weight management. Keep an eye on this one.

Novo Nordisk, the company behind the popular weight-loss drug Wegovy, just pulled the plug on its partnership with telehealth provider Hims & Hers. The reason? Allegations that Hims was playing fast and loose with compounding (mixing their own versions of the drug) and using shady marketing tactics. The news hit Hims & Hers hard—their stock plummeted over 30% in response.

Editor’s Note: This isn’t just corporate drama—it’s a big deal because Wegovy is one of the hottest drugs right now, and Novo Nordisk clearly doesn’t want its reputation tarnished by sketchy practices. For Hims & Hers, losing this deal is a major blow, especially since telehealth companies rely on credibility to keep customers trusting their prescriptions. It also raises questions about how tightly controlled these high-demand drugs should be as more players jump into the market.

Eli Lilly, the pharmaceutical giant behind Ozempic and Wegovy, is making waves with a new weight loss pill that’s showing strong results in trials—up to 23% weight loss for some participants. While the current buzz is around injectable treatments, this oral option could be a game-changer for people who dislike needles. Dr. Roshini Raj from NYU Langone Health breaks down how it stacks up against existing drugs and when it might actually hit pharmacy shelves.

Editor’s Note: Weight loss drugs are having a moment, and this pill could be the next big thing. If approved, it would offer a more convenient alternative to injections, potentially expanding access for millions. With obesity rates climbing, new treatments like this aren’t just about vanity—they’re a serious step toward tackling a major public health issue.

Novo Nordisk’s experimental obesity drug, Amycretin, has shown promising early results—helping patients shed more than 24% of their body weight in a trial. That outperforms the company’s own blockbuster drug Wegovy, which averaged around 17% weight loss. While it’s still early days, the data suggests Amycretin could be a game-changer in the booming weight-loss drug market.

Editor’s Note: Obesity treatments are big business, and Novo Nordisk is already leading the pack with Wegovy. If Amycretin keeps delivering like this in later trials, it could shake up the industry—offering patients even more effective options and tightening Novo’s grip on the market. For anyone watching the space, this is a sign that the weight-loss drug race is far from over.

The NHS in England is rolling out the weight loss injection Mounjaro, but with tight restrictions—only patients deemed most in need will qualify initially. GPs are being given strict guidelines on who can receive it, likely focusing on those with severe obesity or related health risks.

Editor’s Note: Weight loss drugs like Mounjaro can be game-changers, but limited access means not everyone who wants it will get it. This reflects the NHS’s cautious approach—balancing potential benefits against cost and demand. For those struggling with obesity, it’s a hopeful step, but the fine print matters.

Ireland is shipping an unexpected—and incredibly valuable—cargo to the U.S. this year: $36 billion worth of hormones used in blockbuster weight-loss and diabetes drugs like Ozempic and Wegovy. These shipments are so massive that they’ve pushed Ireland, a small country of just five million, into becoming America’s second-largest trade deficit partner, right behind China.